重塑全球药企版图！阿斯利康(AZN.US)拟洽购百时美施贵宝(BMY.US)，或缔造史上最大医药并购案

智通财经08-03

【重塑全球药企版图！阿斯利康(AZN.US)拟洽购百时美施贵宝(BMY.US)，或缔造史上最大医药并购案】智通财经APP获悉，据知情人士透露，阿斯利康(AZN.US)已就收购百时美施贵宝(BMY.US)展开探讨，这桩超级交易若达成，将缔造全球规模最大的制药企业之一。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2656468693?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-03 07:25","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2656468693","market":"us","top_or_hot":-1,"title":"重塑全球药企版图！阿斯利康(AZN.US)拟洽购百时美施贵宝(BMY.US)，或缔造史上最大医药并购案","media":"智通财经","content":"<div>\n<p>【重塑全球药企版图！阿斯利康(AZN.US)拟洽购百时美施贵宝(BMY.US)，或缔造史上最大医药并购案】智通财经APP获悉，据知情人士透露，阿斯利康(AZN.US)已就收购百时美施贵宝(BMY.US)展开探讨，这桩超级交易若达成，将缔造全球规模最大的制药企业之一。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>重塑全球药企版图！阿斯利康(AZN.US)拟洽购百时美施贵宝(BMY.US)，或缔造史上最大医药并购案</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n重塑全球药企版图！阿斯利康(AZN.US)拟洽购百时美施贵宝(BMY.US)，或缔造史上最大医药并购案\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-03 07:25 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【重塑全球药企版图！阿斯利康(AZN.US)拟洽购百时美施贵宝(BMY.US)，或缔造史上最大医药并购案】智通财经APP获悉，据知情人士透露，阿斯利康(AZN.US)已就收购百时美施贵宝(BMY.US)展开探讨，这桩超级交易若达成，将缔造全球规模最大的制药企业之一。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3T34201.USD","symbol_name":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2656468693","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656468693","pubTimestamp":1785713101,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【重塑全球药企版图！阿斯利康(AZN.US)拟洽购百时美施贵宝(BMY.US)，或缔造史上最大医药并购案】智通财经APP获悉，据知情人士透露，阿斯利康(AZN.US)已就收购百时美施贵宝(BMY.US","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4588":"碎股","FXH":"First Trust Health Care AlphaDEX Fund","PPH":"VanEck Pharmaceutical ETF","LU2596442595.SGD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (SGDHDG) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","PILL":"Direxion Daily Pharmaceutical & Medical Bull 3X Shares","AZN":"阿斯利康","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","BK4581":"高盛持仓","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BMY":"施贵宝","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","CURE":"Direxion Daily Healthcare Bull 3X Shares","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4534":"瑞士信贷持仓","XPH":"SPDR S&P Pharmaceuticals ETF","JHMH":"John Hancock Multifactor Healthcare ETF","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","RXD":"ProShares UltraShort Health Care","XBIX":"Corgi U.S. Biotech 2x Daily ETF","LU0237698245.USD":"富达环球地产基金A","SYNB":"PUTNAM BIOREVOLUTION ETF","IEHS":"iShares Evolved U.S. Healthcare Staples ETF","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2272731782.SGD":"Allianz Global Intelligent Cities AM Dis H2-SGD","RXL":"ProShares Ultra Health Care","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","AZNH":"ASTRAZENECA PLC ADRhedged","FHLC":"Fidelity MSCI Health Care Index","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","MEDI":"HARBOR HEALTH CARE ETF","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IHE":"iShares U.S. Pharmaceuticals ETF"},"translate_title":"Reshape the global pharmaceutical company landscape! AstraZeneca (AZN.US) intends to acquire Bristol-Myers Squibb (BMY.US), or create the largest pharmaceutical merger in history","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDI":1.5,"SYNB":1.5,"JHMH":1.5,"IEHS":1.5,"AZNH":0.6,"FXH":1.5,"RXL":1.5,"PILL":1.5,"IHE":1.5,"AZN":1.5,"RXD":1.5,"FHLC":1.5,"PPH":1.5,"XBIX":1.5,"BMY":1.5,"FTXH":0.6,"XPH":1.5,"CURE":1.5},"content_text":"【重塑全球药企版图！阿斯利康(AZN.US)拟洽购百时美施贵宝(BMY.US)，或缔造史上最大医药并购案】智通财经APP获悉，据知情人士透露，阿斯利康(AZN.US)已就收购百时美施贵宝(BMY.US)展开探讨，这桩超级交易若达成，将缔造全球规模最大的制药企业之一。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656468693","isCrawlerRequest":true}